Literature DB >> 17962844

[Dengue hemorrhagic fever serotype and infection pattern in a Colombian endemic area].

Raquel E Ocazionez1, Sergio Y Gómez, Fabián M Cortés.   

Abstract

OBJECTIVE: Describing the relationship between viral serotypes, infection pattern and dengue hemorrhagic fever.
METHODS: 1,545 febrile patients were studied from 1998-2004 in the Santander department of Colombia. Dengue infection was confirmed by IgM ELISA and the virus was isolated in C6/36 cells. Infection pattern was established by detecting IgG antibodies in acute serum. Neutralising antibody titres were investigated in dengue cases occurring during years when less (1998) and more (2001) dengue hemorrhagic cases were reported by using PRNT.
RESULTS: DEN-1 predominance in 1998 and the re-introduction of DEN-3 in 2001 coincided with an epidemic. DEN-2 infection caused more hemorrhagic cases than DEN-3 infection (24,5 % cf 11,2 %; p<0.05). DEN-2 was more associated with secondary infection than DEN-3 (56,8 % cf 15,7 %; p<0.001). An annual decrease of DHF was correlated with decreased DEN-2 dominance (r=0.95; p= 0.01), and secondary infection (r=0.9; p=0.03) and increased DEN-3 predominance (r=-0.91; p=0.03). There were no differences in neutralising antibody titres amongst analysed cases. DEN-1 neutralising antibodies presented the highest titres.
CONCLUSIONS: Change in relative dengue virus serotype abundance was associated with changed infection pattern and DHF frequency. Continuing virological surveillance should become a priority for preventing dengue hemorrhagic fever in endemic areas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962844     DOI: 10.1590/s0124-00642007000200010

Source DB:  PubMed          Journal:  Rev Salud Publica (Bogota)        ISSN: 0124-0064


  8 in total

1.  Variation in inflammatory/regulatory cytokines in secondary, tertiary, and quaternary challenges with dengue virus.

Authors:  Beatriz Sierra; Ana B Pérez; Mayling Alvarez; Gissel García; Katrin Vogt; Eglys Aguirre; Kathrin Schmolke; Hans-Dieter Volk; María G Guzmán
Journal:  Am J Trop Med Hyg       Date:  2012-07-16       Impact factor: 2.345

2.  Dengue in an area of the Colombian Caribbean.

Authors:  Nelson Alvis-Guzman; Heidi Rodríguez-Barreto; Salim Mattar-Velilla
Journal:  Colomb Med (Cali)       Date:  2015-03-30

3.  Simple Prognostic Criteria can Definitively Identify Patients who Develop Severe Versus Non-Severe Dengue Disease, or Have Other Febrile Illnesses.

Authors:  Andrew K I Falconar; Claudia M E Romero-Vivas
Journal:  J Clin Med Res       Date:  2012-01-17

Review 4.  Epidemiological trends of dengue disease in Colombia (2000-2011): a systematic review.

Authors:  Luis Angel Villar; Diana Patricia Rojas; Sandra Besada-Lombana; Elsa Sarti
Journal:  PLoS Negl Trop Dis       Date:  2015-03-19

5.  Co-circulation and simultaneous co-infection of dengue, chikungunya, and zika viruses in patients with febrile syndrome at the Colombian-Venezuelan border.

Authors:  Marlen Yelitza Carrillo-Hernández; Julian Ruiz-Saenz; Lucy Jaimes Villamizar; Sergio Yebrail Gómez-Rangel; Marlen Martínez-Gutierrez
Journal:  BMC Infect Dis       Date:  2018-01-30       Impact factor: 3.090

6.  The prevalence and endemic nature of dengue infections in Guangdong, South China: an epidemiological, serological, and etiological study from 2005-2011.

Authors:  Ru-Ning Guo; Jin-Yan Lin; Lin-Hui Li; Chang-Wen Ke; Jian-Feng He; Hao-Jie Zhong; Hui-Qiong Zhou; Zhi-Qiang Peng; Fen Yang; Wen-Jia Liang
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

7.  Dengue Vaccine: Considerations before Rollout in Colombia.

Authors:  Christian Julian Villabona-Arenas; Raquel Elvira Ocazionez Jimenez; Cinthy Lorena Jimenez Silva
Journal:  PLoS Negl Trop Dis       Date:  2016-06-09

8.  Clinical and epidemiological features of the 2014 large-scale dengue outbreak in Guangzhou city, China.

Authors:  Yong Ping Lin; Yasha Luo; Yuan Chen; Mart Matthias Lamers; Qiang Zhou; Xiao Han Yang; Sumana Sanyal; Chris Ka Pun Mok; Zhong Min Liu
Journal:  BMC Infect Dis       Date:  2016-03-01       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.